Document Detail


Hormone response in ovarian cancer: time to reconsider as a clinical target?
MedLine Citation:
PMID:  23045324     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ovarian cancer is the sixth most common cancer worldwide among women in developed countries and the most lethal of all gynecologic malignancies. There is a critical need for the introduction of targeted therapies to improve outcome. Epidemiological evidence suggests a critical role for steroid hormones in ovarian tumorigenesis. There is also increasing evidence from in vitro studies that estrogen, progestin, and androgen regulate proliferation and invasion of epithelial ovarian cancer cells. Limited clinical trials have shown modest response rates; however, they have consistently identified a small subset of patients that respond very well to endocrine therapy with few side effects. We propose that it is timely to perform additional well-designed trials that should include biomarkers of response.
Authors:
Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Related Documents :
25138444 - Development and evaluation of a new survey instrument to measure the quality of colorec...
24122784 - Associations among prognostic understanding, quality of life, and mood in patients with...
23052564 - Biomarkers spectral subspace for cancer detection.
24621964 - "i'm a survivor, go study that word and you'll see my name": adolescent and cancer iden...
25138444 - Development and evaluation of a new survey instrument to measure the quality of colorec...
18609154 - Decreased death from gastric cancer by endoscopic screening: association with a populat...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-11-09
Journal Detail:
Title:  Endocrine-related cancer     Volume:  19     ISSN:  1479-6821     ISO Abbreviation:  Endocr. Relat. Cancer     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-12     Completed Date:  2013-12-31     Revised Date:  2014-04-21    
Medline Journal Info:
Nlm Unique ID:  9436481     Medline TA:  Endocr Relat Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  R255-79     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents, Hormonal / therapeutic use
Female
Hormones / metabolism*
Humans
Neoplasms, Glandular and Epithelial / drug therapy,  epidemiology,  metabolism*
Ovarian Neoplasms / drug therapy,  epidemiology,  metabolism*
Receptors, Cell Surface / metabolism
Grant Support
ID/Acronym/Agency:
P50 CA136393/CA/NCI NIH HHS; T32 GM008424/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Hormones; 0/Receptors, Cell Surface
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  [Experience with cardiac magnetic resonance imaging in patient management at the Markusovszky Hospit...
Next Document:  Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas.